The continuing evolution of targeted therapy for inflammatory skin disease.

Schlapbach, Christoph; Navarini, A A (2016). The continuing evolution of targeted therapy for inflammatory skin disease. Seminars in immunopathology, 38(1), pp. 123-133. Springer 10.1007/s00281-015-0524-2

[img] Text
art%3A10.1007%2Fs00281-015-0524-2.pdf - Published Version
Restricted to registered users only until 1 February 2021.
Available under License Publisher holds Copyright.

Download (757kB) | Request a copy
[img]
Preview
Text
akzeptiertes Manuskript_93916.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (646kB) | Preview

Treatment of inflammatory skin disease has evolved from non-specific suppression of immune cells to increasingly precise targeting and modulation of immune mechanisms at all levels. This has led to dramatic treatment successes and deepened understanding of the pathophysiology. The cycle of in vitro studies, animal models, clinical trials, and case series of non-primary indications is a feedback loop that informs and guides the design of ever better disease models and therapeutic targets. Not only are we constantly discovering new molecules driving skin inflammation, we have also found that psoriasis and other autoimmune conditions are driven by distinct mediators occurring in early and late phases, which could be an opportunity for phase-specific or multipronged interventions. The deeper our mechanistic understanding, the more likely we will be able to discover subtle strategies to reprogram each patients' immune cells without having to dampen or eliminate their protective effects against pathogens and tumors. Lastly, ongoing genomic studies might soon confirm interesting genetic markers for predictive personalized medicine, the earliest currently being evaluated in psoriasis such as HLA-Cw6 and TNFAIP3. Taken together, the continued evolution of immune therapies in skin will potentially allow an unprecedented form of medicine that is not bent on silencing the pathogenic mechanism, but rather aims at using subtle interventions to shepherd the immune cell swarm back on the correct path.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Schlapbach, Christoph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1863-2297

Publisher:

Springer

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

01 Mar 2017 09:05

Last Modified:

15 Mar 2017 08:48

Publisher DOI:

10.1007/s00281-015-0524-2

PubMed ID:

26423993

Uncontrolled Keywords:

Biologics; Combined; Inflammation; Phase-specific; Swarm

BORIS DOI:

10.7892/boris.93916

URI:

https://boris.unibe.ch/id/eprint/93916

Actions (login required)

Edit item Edit item
Provide Feedback